Prexasertib + Irinotecan for Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Recruiting in Palo Alto (17 mi)

Overseen byEmily Slotkin, MD

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to test whether the study drug prexasertib is a safe and effective treatment for people with DSRCT or RMS when given in combination with the standard drugs irinotecan and temozolomide. The study will test different doses of prexasertib in combination with irinotecan and temozolomide to find the highest dose of prexasertib that causes few or mild side effects in participants.

Research Team

Emily Slotkin, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for patients aged ≥12 months with advanced or metastatic desmoplastic small round cell tumor or rhabdomyosarcoma that's resistant to standard treatments. They must have measurable disease, be in a certain health condition (Karnofsky/Lansky score), and have adequate organ function. Pregnant individuals, those with uncontrolled infections, heart conditions like congestive heart failure, or hypersensitivity to irinotecan are excluded.

Inclusion Criteria

absolute neutrophil count (ANC) ≥ 1500/mm^3

I have recovered from side effects of previous cancer treatments, except for hair loss.

My kidney function is normal or near normal.

See 26 more

Exclusion Criteria

Patients with known hypersensitivity to irinotecan or its excipients are not eligible

I do not have a history of heart issues like Torsades de Pointes, congestive heart failure, or family history of prolonged QT syndrome.

Patients for whom the investigator deems that irinotecan and temozolomide are not appropriate are not eligible

See 3 more

Treatment Details

Interventions

Irinotecan (Topoisomerase I inhibitor)
Prexasertib (CHK1 Inhibitor)

Trial OverviewThe study tests the safety and effectiveness of prexasertib combined with standard drugs irinotecan and temozolomide in treating specific tumors. It aims to find the highest dose of prexasertib that participants can tolerate with few or mild side effects.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Prexasertib and IrinotecanExperimental Treatment2 Interventions

Patients will have extent of disease scans following every 2 cycles (every 6 weeks on dose levels 0-3, and every 8 weeks on dose level -1 (if required). Patients will be allowed to continue therapy as long as they do not experience dose-limiting toxicities or progression of disease.

Irinotecan is already approved in Japan, Canada for the following indications: